New Advances in the Understanding and Treatment of Addiction
ANNOUNCEMENT OF 2003 SPECIAL ISSUE
ANNOUNCEMENT: CHANGE OF EDITOR
Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice
Model genetic systems. Commentary on Stephens et al. ‘Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice’
Behavioral pharmacologists: Don't just say “no” to knockout mice. Commentary on Stephens et al. ‘Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice’
Analysing mice. Commentary on Stephens et al. ‘Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice’
Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies
There is more to dopamine than just pleasure. Commentary on Volkow et al. ‘Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies’
From rats to humans and return: testing addiction hypotheses by combined PET imaging and self-reported measures of psychostimulant effects. Commentary on Volkow et al. ‘Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies’
Effect of cocaine and sucrose withdrawal period on extinction behavior, cue-induced reinstatement, and protein levels of the dopamine transporter and tyrosine hydroxylase in limbic and cortical areas in rats
Increases in the reinforcing efficacy of cocaine after particular histories of reinforcement
Reinstatement and spontaneous recovery of cocaine-seeking following extinction and different durations of withdrawal
Cocaine sensitization in the mouse using a cumulative dosing regime
Diazepam withdrawal-induced anxiety and place aversion in the rat: differential effects of two chronic diazepam treatment regimes
The effects of alprazolam and buspirone in light and moderate female social drinkers
Addictive and nonaddictive smoking as related to responsivity to neurotransmitter systems
SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody
Abstracts of a Workshop on New Advances in the Understanding and Treatment of Addiction, a joint meeting of the European Behavioural Pharmacology Society and the British Association for Psychopharmacology, Brighton, 19–21 September 2002